PL BioScience Reveals Fall 2025 Conferences Attendance PL BioScience announces participation in upcoming conferences this fall PL BioScience has revealed its participation in six upcoming Fall 2025 conferences. As part of its global strategy, the company will be represented in the following conferences in Asia and Europe:
PL BioScience Announces Major Site Expansion in September 2025 Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone
The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements, including redirection of HPL customers from Macopharma to PL BioScience. PL BioScience GmbH, a German life science company specializing in the production and
Becoming human: GMP-compliant supplements for cell therapy Don't miss our upcoming first webinar and live Q&A hosted by our Field Application Scientist Dr. Silke Isenhardt! Titled "Moving Towards Animal Free Cell Culture Media: Human Platelet Lysate - An Innovative Solution to FBS", register now to learn about
Becoming human: GMP-compliant supplements for cell therapy We were recently interviewed by European biotech media company Labiotech regarding our thoughts on cell culture reagent challenges, and our line of ELAREM™ Human Platelet Lysate (HPL) for cell therapy. The article features thoughts and quotes from CEO &
"How we conduct our research is often just as important as the results of our research" Sustainability and Ethics are wide-reaching, interdisciplinary issues that often fall to the wayside during the process of modern scientific research. We compiled just some of the ways PL BioScience and ELAREM™
What are the most used animal-derived materials in scientific experiments? What are the main issues in terms of production and use? These were the two main questions that Cassotta et al. attempted to answer in their publication about "A worldwide survey on the use of
Nutrient media for the development of regenerative therapies In the latest interview at bionity.com, our CEO Dr. Hatim Hemeda talked about the history and background idea of PL BioScience to develop nutrient media for the development of regenerative therapies. As a young life science company we develop, produce
Why Human Platelet Lysate outperforms Human Serum for Stem Cell Therapy "Which media should I choose for my application?" - There is no short answer because it depends on the application aim of the cell therapy, the production process and sometimes on the cell types and
Preliminary report phase 1 clinical trial using a xeno-free & GMP compliant protocol with Human Platelet Lysate Madani et al. reported the short term safety of Placenta derived Mesenchymal Stem Cells (PLMSCs) transplanted in 4 children (Type 1 Diabetes Mellitus patients (T1DM)). The manufacturing of PLMSCs to the
'Accelerating research and discovery' – Human Platelet Lysate in North America 'Accelerating research and discovery'. The mission of the team at Captivate Bio perfectly fits our mission: Providing one solution for all development stages – Human Platelet Lysate. From the beginning, we saw strong synergies between our companies.
Virtual 10th international meeting: 'From Fundamental Biology to Translational Concepts' The international congress of the Stem Cell Network NRW will be held online. On 29 and 30 March 2021 you will have the opportunity to participate in lectures, "meet the speaker" sessions and the industry exhibition. Rising
Vero cells are used in the development of Covid-19 vaccines Vero cells are used a lot in research and industry. Time to have a closer look at this cell line: Vero cells are continuous cell lines that was derived from the kidney of an African green monkey
Today is world cancer day A great opportunity to raise awareness for cancer patients and survivors as well as for cancer research and therapies. Cancer is one of the most serious diseases causing almost one in six deaths globally, which is estimated to equal 9.6 million
TALK & LIVE Q&A with our CEO Dr. Hatim Hemeda On 9 February 2021, between 13:30-18:00, we will be at the Life Science Tuesday from the ÖGMBT - Austrian Association of Molecular Life Sciences and Biotechnology in a session about tissue engineering and regenerative medicine. This Life
Animal experiments are one of the most discussed topics in research and in our society. We neither want to condemn animal experiments nor do we want to trivialize this topic. What we want is to raise awareness and open a fact-based discussion about it. Animal experiments are
ELAREM™ Prime is the worldwide first affordable cell culture supplement based on human platelets offering the same benefits as FBS – in an animal serum-free environment. What is ELAREM™ Prime? It is derived from reused transfusion-approved platelets. These platelets can no longer be used for blood transfusions,
Introducing our new human Platelet Lysate brand name: ELAREM™ As a university spin-off, we started manufacturing our human Platelet Lysates (hPL) back in 2015, as ‘PL Solution’ products. For more than five years, you may know our human Platelet Lysates under this name. It is time
We look forward attending the virtual DxPx international partnering conference from 17-21st November 2020. Even if this year will be special due to Covid19, we are happy to connect with you on a virtual level. For the second time, the DxPx partnering conference is a parallel event
A new publication from Kouroupis et al. published in CYTOTHERAPY in July 2020 found out that infrapatellar fat pad (IFP)-mesenchymal stem cells (MSCs) manufactured with human Platelet Lysate (hPL) show enhanced immunomodulatory properties. Findings have potential for a minimally invasive cell therapy for joint disease The authors even
